glp 1 cardiovascular effects disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Protective Properties of GLP-1

The 0.25mg starting dose differs from the 0.5mg week-five dose and the 1.0mg maintenance dose

This is a significant concern for businesses who might be adversely affected by lower volumes of food sales to obese individuals

What they do mean is that bone health monitoring - a baseline DXA scan, adequate protein and calcium intake, resistance training - is a necessary part of responsible GLP-1 therapy, not an optional extra

Excessive NMDA receptor activation triggers Ca 2+ influx, leading to mitochondrial dysfunction and OS, ultimately resulting in the death of neurons due to excitotoxicity [21]

Zhang et al., 2022) which has antiapoptotic cellular effect (Niture and Jaiswal, 2012

References Novo Nordisk CagriSema titration scheme, cagrilintide amylin-receptor pharmacology, and REDEFINE phase 3 programme